Segment Information

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company operates its business and reports its results through three operating and reportable segments: dispensary, patient services, and clinical trials & other in accordance with ASC 280. See Note 2 for a summary of the Company’s policy on segment information.

Summarized financial information for the Company’s segments is shown in the following tables:

(in thousands)	Year Ended December 31,
	2022		2021
Revenue
Patient services	$	166,785	$	124,074
Dispensary	79,343		72,550
Clinical trials & other	6,355		6,379
Consolidated revenue	252,483		203,003
Direct costs
Patient services	134,761		99,401
Dispensary	65,111		62,102
Clinical trials & other	518		652
Total segment direct costs	200,390		162,155
Depreciation expense
Patient services	1,202		659
Dispensary	4		1
Clinical trials & other	1		123
Total segment depreciation expense	1,207		783
Amortization of intangible assets
Patient services	2,675		2,305
Dispensary	—		—
Clinical trials & other	211		211
Total segment amortization	2,886		2,516
Operating income
Patient services	28,147		21,709
Dispensary	14,228		10,447
Clinical trials & other	5,625		5,393
Total segment operating income	48,000		37,549
Goodwill impairment charges
Patient services	9,944		—
Dispensary	—		—
Clinical trials & other	—		—
Total impairment charges	9,944		—
Selling, general and administrative expense	119,689		83,365
Non-segment depreciation and amortization	318		42
Total consolidated operating loss	$	(81,951)	$	(45,858)

(in thousands)	December 31, 2022		December 31, 2021
Assets
Patient services	$	64,869	$	44,223
Dispensary	7,194		4,277
Clinical trials & other	11,496		14,504
Non-segment assets	178,106		140,435
Total assets	$	261,665	$	203,439